| Submission declined on 27 April 2024 by
ToadetteEdit (
talk). This submission's references do not show that the subject
qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published,
reliable,
secondary sources that are
independent of the subject (see the
guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see
technical help and learn about
mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 19 July 2023 by
Tutwakhamoe (
talk). This submission's references do not show that the subject
qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published,
reliable,
secondary sources that are
independent of the subject (see the
guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see
technical help and learn about
mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by
Tutwakhamoe 10 months ago. | |
| Submission declined on 7 March 2023 by
Tails Wx (
talk). This submission is not adequately supported by
reliable sources. Reliable sources are required so that information can be
verified. If you need help with referencing, please see
Referencing for beginners and
Citing sources. Declined by
Tails Wx 15 months ago. | |
| Submission declined on 10 November 2022 by
97198 (
talk). This submission's references do not show that the subject
qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published,
reliable,
secondary sources that are
independent of the subject (see the
guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see
technical help and learn about
mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by
97198 19 months ago. | |
Comment: Many of the sources did not mentioned the subject at all, and those that did are either published by his institutions, lacks significant coverage, or primarily based on his own publications for sources. Multiple significant coverage are required to show that the subject passes
WP:NBIO.
Tutwakhamoe (
talk) 00:11, 19 July 2023 (UTC)
- Comment: All cited sources are either written by the subject or have a close connection with the subject.
97198 (
talk) 01:30, 10 November 2022 (UTC)
Stanley T Crooke | |
|---|---|
| Born | March 28, 1945 |
| Education | MD - Baylor College of Medicine, Houston, TX, 1974
PhD Pharmacology - Baylor College of Medicine, Houston, TX, 1971 BS Pharmacy - Butler University, Indianapolis, IN, 1966 |
Stanley T. Crooke is an American pharmacologist and the founding CEO of Ionis Pharmaceuticals, an RNA-targeted therapeutics company. In 1989, he opened Isis Pharmaceuticals, now known as Ionis, which would go on to pioneer a drug discovery platform, antisense oligonucleotides [1]. Over the years, Ionis has developed several drugs including Spinraza [2], which is designed to treat spinal muscular atrophy (SMA). In 2020, Crooke founded the N-Lorem foundation, a non-profit designed to take advantage of the technology discovered at Ionis to provide experimental treatment to patients with extremely rare genetic disorders.
Early Life and Education
Stanley Crooke grew up in southwest Indianapolis. [3] Coming from a working-class family, Crooke was the first in his family to finish high school. He studied pharmacy at Butler University, and attempted law school for one week before dropping out. Crooke then attended the Baylor College of Medicine, where he completed a combined MD-PhD program in pharmacology. [3]
Career
After working at Bristol Laboratories, Crooke transitioned to research and development at GlaxoSmithKline. [2] In 1989, he founded Ionis Pharmaceuticals, initially named Isis Pharmaceuticals, serving as its CEO until 2019. During his tenure, several antisense-oligonucleotide therapeutics were developed, including:
- Vitravene: For the treatment of cytomegalovirus retinitis (CMV).
- Volanesorsen: For the treatment of familial chylomicronemia syndrome (FCS).
- Kynamro: An orphan drug for managing homozygous familial hypercholesterolemia (HoFH).
- Tegsedi: For the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR).
Dr. Crooke has also worked as an adjunct professor in the Departments of Pharmacology at the University of Pennsylvania, the Baylor College of Medicine and UCSD, the Department of Anatomy and Cell Biology at UCLA, the Department of Biology at San Diego State University.
In 2020, Dr. Crooke founded the n-Lorem Foundation [4], a non-profit organization that focuses on creating individual experimental treatments for patients with rare genetic diseases. As a non-profit, they provide experimental antisense oligonucleotides to patients for free. Here, he developed an ASO to be the first medication to treat a mutation in the KIF1A gene. He was recognized by the SD500 in 2023 as one of the most influential people in San Diego. [5]
Notable Awards
Crooke was awarded the 2019 Massry Prize along with Ryszard Kole. [6]
Personal Life
Stanley Crooke is married to Rosanne Crooke, who is also a pharmacologist. [2]
References
- ^ Herper, Matthew. "After 24 Years Of Struggle, Has Stan Crooke Finally Birthed An Age Of Antisense?". Forbes. Retrieved 2024-06-04.
- ^ a b c "Stanley Crooke on finally making sense out of antisense". Chemical & Engineering News. Retrieved 2024-06-03.
- ^ a b "The Personal Journey of Stanley Crooke, the Creation and Development of Ionis, and Beyond". Oligonucleotide Therapeutics Society. 2022-09-08. Retrieved 2023-01-18.
- ^ mikejaram. "Leadership Team". nlorem. Retrieved 2024-06-04.
- ^ "SD500: San Diego's Most Influential People 2023 Archives". San Diego Business Journal. Retrieved 2024-06-04.
- ^ "Past Laureates". Massry Prize. Retrieved 2024-06-03.
| Submission declined on 27 April 2024 by
ToadetteEdit (
talk). This submission's references do not show that the subject
qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published,
reliable,
secondary sources that are
independent of the subject (see the
guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see
technical help and learn about
mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
| |
| Submission declined on 19 July 2023 by
Tutwakhamoe (
talk). This submission's references do not show that the subject
qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published,
reliable,
secondary sources that are
independent of the subject (see the
guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see
technical help and learn about
mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by
Tutwakhamoe 10 months ago. | |
| Submission declined on 7 March 2023 by
Tails Wx (
talk). This submission is not adequately supported by
reliable sources. Reliable sources are required so that information can be
verified. If you need help with referencing, please see
Referencing for beginners and
Citing sources. Declined by
Tails Wx 15 months ago. | |
| Submission declined on 10 November 2022 by
97198 (
talk). This submission's references do not show that the subject
qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published,
reliable,
secondary sources that are
independent of the subject (see the
guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see
technical help and learn about
mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by
97198 19 months ago. | |
- Comment: Many of the sources did not mentioned the subject at all, and those that did are either published by his institutions, lacks significant coverage, or primarily based on his own publications for sources. Multiple significant coverage are required to show that the subject passes
WP:NBIO.
Tutwakhamoe (
talk) 00:11, 19 July 2023 (UTC)
- Comment: All cited sources are either written by the subject or have a close connection with the subject.
97198 (
talk) 01:30, 10 November 2022 (UTC)
Stanley T Crooke | |
|---|---|
| Born | March 28, 1945 |
| Education | MD - Baylor College of Medicine, Houston, TX, 1974
PhD Pharmacology - Baylor College of Medicine, Houston, TX, 1971 BS Pharmacy - Butler University, Indianapolis, IN, 1966 |
Stanley T. Crooke is an American pharmacologist and the founding CEO of Ionis Pharmaceuticals, an RNA-targeted therapeutics company. In 1989, he opened Isis Pharmaceuticals, now known as Ionis, which would go on to pioneer a drug discovery platform, antisense oligonucleotides [1]. Over the years, Ionis has developed several drugs including Spinraza [2], which is designed to treat spinal muscular atrophy (SMA). In 2020, Crooke founded the N-Lorem foundation, a non-profit designed to take advantage of the technology discovered at Ionis to provide experimental treatment to patients with extremely rare genetic disorders.
Early Life and Education
Stanley Crooke grew up in southwest Indianapolis. [3] Coming from a working-class family, Crooke was the first in his family to finish high school. He studied pharmacy at Butler University, and attempted law school for one week before dropping out. Crooke then attended the Baylor College of Medicine, where he completed a combined MD-PhD program in pharmacology. [3]
Career
After working at Bristol Laboratories, Crooke transitioned to research and development at GlaxoSmithKline. [2] In 1989, he founded Ionis Pharmaceuticals, initially named Isis Pharmaceuticals, serving as its CEO until 2019. During his tenure, several antisense-oligonucleotide therapeutics were developed, including:
- Vitravene: For the treatment of cytomegalovirus retinitis (CMV).
- Volanesorsen: For the treatment of familial chylomicronemia syndrome (FCS).
- Kynamro: An orphan drug for managing homozygous familial hypercholesterolemia (HoFH).
- Tegsedi: For the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR).
Dr. Crooke has also worked as an adjunct professor in the Departments of Pharmacology at the University of Pennsylvania, the Baylor College of Medicine and UCSD, the Department of Anatomy and Cell Biology at UCLA, the Department of Biology at San Diego State University.
In 2020, Dr. Crooke founded the n-Lorem Foundation [4], a non-profit organization that focuses on creating individual experimental treatments for patients with rare genetic diseases. As a non-profit, they provide experimental antisense oligonucleotides to patients for free. Here, he developed an ASO to be the first medication to treat a mutation in the KIF1A gene. He was recognized by the SD500 in 2023 as one of the most influential people in San Diego. [5]
Notable Awards
Crooke was awarded the 2019 Massry Prize along with Ryszard Kole. [6]
Personal Life
Stanley Crooke is married to Rosanne Crooke, who is also a pharmacologist. [2]
References
- ^ Herper, Matthew. "After 24 Years Of Struggle, Has Stan Crooke Finally Birthed An Age Of Antisense?". Forbes. Retrieved 2024-06-04.
- ^ a b c "Stanley Crooke on finally making sense out of antisense". Chemical & Engineering News. Retrieved 2024-06-03.
- ^ a b "The Personal Journey of Stanley Crooke, the Creation and Development of Ionis, and Beyond". Oligonucleotide Therapeutics Society. 2022-09-08. Retrieved 2023-01-18.
- ^ mikejaram. "Leadership Team". nlorem. Retrieved 2024-06-04.
- ^ "SD500: San Diego's Most Influential People 2023 Archives". San Diego Business Journal. Retrieved 2024-06-04.
- ^ "Past Laureates". Massry Prize. Retrieved 2024-06-03.